PLRZ: 282% | Polyrizon Secures GMP Manufacturing Partnership With Eurofins CDMO Amatsiaquitaine, Advancing Toward PL-14 Allergy Blocker Clinical Trial In 2025
CRVS: 24% | Corvus Pharmaceuticals shares are trading higher after the company announced it will report on December 18 interim data from its Phase 1 clinical trial evaluating Soquelitinib in patients with moderate to severe atopic dermatitis.
OKLO: 10% | Oklo And Switch Partner To Deploy 12 GW Of Advanced Nuclear Power